Key facts
- This page summarizes Terrie Kellmeyer's Form 3 filing for ANAVEX LIFE SCIENCES CORP. (AVXL).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 May 2026, 16:15.
Terrie Kellmeyer - 04 May 2026 Form 3 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)
- Reporting relationship
- Interim CEO
- Issuer ticker
- AVXL
- Reported as of
- 04 May 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Terrie Kellmeyer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Terrie Kellmeyer filed Form 3 for ANAVEX LIFE SCIENCES CORP. (AVXL) on 14 May 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002135020
Primary reporting owner
Kellmeyer Terrie
- Relationship
- Interim CEO
- Address
- 630 5TH AVENUE, 20TH FLOOR, NEW YORK
- Signature
- /s/ Terrie Kellmeyer
- Signature date
- 14 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVXL
holding
Derivative
Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,668
- Exercise price
- $7.21
- Footnotes
- F1
AVXL
holding
Derivative
Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $5.36
- Footnotes
- F2
AVXL
holding
Derivative
Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $8.58
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes 35,001 fully vested options and 11,667 unvested options that will vest in two substantially equal tranches on June 30, 2026 and September 30, 2026.
Footnote F2
Includes 2,500 fully vested options and 5,000 options which will vest in two equal tranches based on two performance milestones.
Footnote F3
Includes 25,000 fully vested options and 25,000 options which will vest in two equal tranches based on two performance milestones.